Donor insulin use predicts beta‐cell function after islet transplantationCitation formats
Standard
Donor insulin use predicts beta‐cell function after islet transplantation. / Shapey, Iestyn M; Summers, Angela; Yiannoullou, Petros; Khambalia, Hussein; Fullwood, Catherine; Hanley, Neil A; Casey, John; Forbes, Shareen; Rosenthal, Miranda; Johnson, Prv; Choudhary, P; Bushnell, James; Shaw, James Am; Augustine, T; Rutter, Martin K; Van Dellen, D.
In: Diabetes, Obesity and Metabolism, 25.05.2020.Research output: Contribution to journal › Article › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Donor insulin use predicts beta‐cell function after islet transplantation
AU - Shapey, Iestyn M
AU - Summers, Angela
AU - Yiannoullou, Petros
AU - Khambalia, Hussein
AU - Fullwood, Catherine
AU - Hanley, Neil A
AU - Casey, John
AU - Forbes, Shareen
AU - Rosenthal, Miranda
AU - Johnson, Prv
AU - Choudhary, P
AU - Bushnell, James
AU - Shaw, James Am
AU - Augustine, T
AU - Rutter, Martin K
AU - Van Dellen, D
PY - 2020/5/25
Y1 - 2020/5/25
N2 - Insulin is routinely used to manage hyperglycaemia in organ donors and during the peri‐transplant period in islet transplant recipients. However, it is unknown whether Donor Insulin Use (DIU) predicts beta‐cell dysfunction after islet transplantation. We reviewed data from the United Kingdom (UK) Transplant Registry and the UK Islet Transplant Consortium – all first‐time transplants between 2008–2016 were included. Linear regression models determined associations between DIU, median and coefficient of variation (CV) peri‐transplant glucose levels and 3‐month islet graft function. In 91 islet cell transplant recipients, DIU was associated with lower islet function assessed by BETA‐2 scores (β [SE] ‐3.5 [1.5], p = 0.02), higher 3‐month post‐transplant HbA1c levels (5.4 [2.6] mmol/mol, p = 0.04) and lower fasting c‐peptide levels (−107.9 [46.1] pmol/l, p = 0.02). Glucose at 10512 time points were recorded during the first 5 days peri‐transplant ‐ the median (IQR) daily glucose level was 7.9 (7.0–8.9) mmol/L and glucose CV: 28 (21–35)%. Neither median glucose levels nor glucose CV predicted outcomes post‐transplantation. Data on DIU predicts beta‐cell dysfunction 3‐months after islet transplantation and could help improve donor selection and transplant outcomes.
AB - Insulin is routinely used to manage hyperglycaemia in organ donors and during the peri‐transplant period in islet transplant recipients. However, it is unknown whether Donor Insulin Use (DIU) predicts beta‐cell dysfunction after islet transplantation. We reviewed data from the United Kingdom (UK) Transplant Registry and the UK Islet Transplant Consortium – all first‐time transplants between 2008–2016 were included. Linear regression models determined associations between DIU, median and coefficient of variation (CV) peri‐transplant glucose levels and 3‐month islet graft function. In 91 islet cell transplant recipients, DIU was associated with lower islet function assessed by BETA‐2 scores (β [SE] ‐3.5 [1.5], p = 0.02), higher 3‐month post‐transplant HbA1c levels (5.4 [2.6] mmol/mol, p = 0.04) and lower fasting c‐peptide levels (−107.9 [46.1] pmol/l, p = 0.02). Glucose at 10512 time points were recorded during the first 5 days peri‐transplant ‐ the median (IQR) daily glucose level was 7.9 (7.0–8.9) mmol/L and glucose CV: 28 (21–35)%. Neither median glucose levels nor glucose CV predicted outcomes post‐transplantation. Data on DIU predicts beta‐cell dysfunction 3‐months after islet transplantation and could help improve donor selection and transplant outcomes.
U2 - 10.1111/dom.14088
DO - 10.1111/dom.14088
M3 - Article
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
ER -